EYSINS, Switzerland, June 5, 2014 /CNW/ - In line with its mission of market innovator, Biosafe is proud to announce the launch of the SepaMax multiprocessing device, on the occasion of the International Cord Blood Symposium in San Francisco.
SepaMax is designed for high throughput cell processing. Based on Biosafe's industry-leading Sepax technology, it offers six processing modules in a compact package, which are centrally controlled. Combined with a very cost-effective kit and protocol, SepaMax can process fully automatically up to 20 units / hour, making it very attractive for large-scale cord blood bank production.
Olivier Waridel, CEO of Biosafe commented: "The new SepaMax device complements Biosafe's portfolio, offering quality, high throughput and automation in a single package. SepaMax is particularly suitable for large cord blood banks looking for high performance coupled with cost effectiveness. SepaMax is a brand new technology platform, which will host new applications for bioprocessing in the future as well."
About the Biosafe Group
Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and São Paulo) and is present in more than 50 countries, either directly or through distributors.
SOURCE: Biosafe Group S.A.
For further information: Christopher Bolton, CFO, Biosafe Group SA, +41-22-365-27-27, email@example.com, http://www.biosafe.ch